Pfizer Inc said on Monday it has filed a second lawsuit against its controlling shareholder, Metsera, and Novo Nordisk in a ...

Lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...

This second lawsuit represents an escalation of Pfizer’s efforts to block the Danish drug giant’s $9bn offer for Metsera, ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of ...

Drugmaker Pfizer on Friday sued obesity-drug developer Metsera and Novo Nordisk, seeking to block Metsera from terminating ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.